Alpha 2.0
Login Register
» Articles » PMID: 38852822

Provision of Medications to Treat Opioid Use Disorder Via a Mobile Health Unit: A Scoping Review

Overview
Journal J Subst Use Addict Treat
Specialty Psychiatry
Date 2024 Jun 9
PMID 38852822
Authors
Amelia Bailey
Alyssa DaCunha
Siena C Napoleon
Augustine W Kang
Madeleine Kemo
Rosemarie A Martin
Affiliations
Soon will be listed here.
Abstract

Introduction: Mobile health units (MHUs) provide a variety of low-barrier services to populations that face systemic barriers to healthcare access. However, MHUs are not a common delivery method for medications to treat opioid use disorder (MOUD), and, of these, there is no consensus regarding MHU targeted objectives and outcomes. This scoping review seeks to summarize the state of the literature examining the delivery of MOUD by MHUs in the United States.

Methods: A search of PubMed, PsycInfo, and CINAHL on February 21, 2023, found 223 articles. Two authors completed title and abstract and full text reviews and extracted data relevant to intervention and study design, program objectives, and study outcomes. Ten articles fit the study's inclusion criteria (nine total interventions).

Results: Of the 10 studies, six were cohort designs, three were cross-sectional (one with qualitative interviews), and one study conducted qualitative interviews only. Most studies were located in the Northeastern United States. MHU interventions primarily aimed to provide MOUD and to retain populations in treatment. Two interventions aimed to engage patients and then transfer them to fixed-site MOUD providers. Across four interventions that provided buprenorphine, 1- and 3-month retention rates varied from 31.6 % to 72.3 % and 26.2 % to 58.5 %, respectively. Qualitative interviews found that MOUD delivery from the MHU was characterized by less stigma/judgment and greater privacy compared to fixed-site, and it was flexible and low-barrier. MHUs were reportedly underutilized by the target populations, suggesting a lack of awareness from community members with opioid use disorder.

Conclusions: MHUs that deliver MOUD are both under-provided and -utilized. Future research should continue to assess MOUD provision from MHUs with an emphasis on robust study design, application to other formulations of MOUD, and evaluation of outcomes such as participant satisfaction and key informant perceived challenges.

Registration: Submitted to Open Science Framework (OSF) Repository on February 6, 2023.

References
1.
Rosecrans A, Harris R, Saxton R, Cotterell M, Zoltick M, Willman C . Mobile low-threshold buprenorphine integrated with infectious disease services. J Subst Abuse Treat. 2021; 133:108553. PMC: 8702567. DOI: 10.1016/j.jsat.2021.108553. View
2.
Breve F, Batastini L, LeQuang J, Marchando G . Mobile Narcotic Treatment Programs: On the Road Again?. Cureus. 2022; 14(3):e23221. PMC: 9012571. DOI: 10.7759/cureus.23221. View
3.
Krawczyk N, Williams A, Saloner B, Cerda M . Who stays in medication treatment for opioid use disorder? A national study of outpatient specialty treatment settings. J Subst Abuse Treat. 2021; 126:108329. PMC: 8197774. DOI: 10.1016/j.jsat.2021.108329. View
4.
Gordon M, Vocci F, Fitzgerald T, OGrady K, OBrien C . Extended-release naltrexone for pre-release prisoners: A randomized trial of medical mobile treatment. Contemp Clin Trials. 2016; 53:130-136. PMC: 5274608. DOI: 10.1016/j.cct.2016.12.015. View
5.
Hollander M, Chang C, Douaihy A, Hulsey E, Donohue J . Racial inequity in medication treatment for opioid use disorder: Exploring potential facilitators and barriers to use. Drug Alcohol Depend. 2021; 227:108927. PMC: 8464525. DOI: 10.1016/j.drugalcdep.2021.108927. View